Wiley Bros. Aintree Capital, LLC Virios Therapeutics, Inc. Call Options Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VIRI
# of Institutions
28Shares Held
1.12MCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA231KShares$1.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA209KShares$927,4400.0% of portfolio
-
Ubs Group Ag186KShares$826,1150.0% of portfolio
-
Hrt Financial LP New York, NY81.6KShares$362,1880.0% of portfolio
-
Two Sigma Securities, LLC New York, NY53.4KShares$237,0600.0% of portfolio
About Virios Therapeutics, Inc.
- Ticker VIRI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,330,400
- Market Cap $81.4M
- Description
- Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...